State of Wyoming Purchases 9,987 Shares of Qiagen N.V. $QGEN

Key Points

• The State of Wyoming increased its stake in Qiagen N.V. by 358.2%, owning a total of 12,775 shares worth $513,000 after acquiring an additional 9,987 shares in the first quarter.
• Qiagen's recent earnings report showed an EPS of $0.60, meeting analysts’ expectations, with revenues up 7.7% year-over-year at $533.54 million.
• Several analysts have recently adjusted their price targets for Qiagen, with Bank of America raising its target from $50.00 to $53.00, indicating a positive outlook for the stock.

State of Wyoming lifted its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 358.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,775 shares of the company's stock after purchasing an additional 9,987 shares during the quarter. State of Wyoming's holdings in Qiagen were worth $513,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in QGEN. SVB Wealth LLC bought a new position in shares of Qiagen in the first quarter worth $31,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Qiagen in the first quarter worth $94,000. Tower Research Capital LLC TRC increased its holdings in shares of Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after purchasing an additional 2,204 shares during the period. GAMMA Investing LLC increased its holdings in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the period. Finally, Federated Hermes Inc. bought a new position in shares of Qiagen in the first quarter worth $150,000. Institutional investors own 70.00% of the company's stock.

Qiagen Stock Performance

NYSE QGEN opened at $46.53 on Friday. The company has a 50-day simple moving average of $48.71 and a two-hundred day simple moving average of $44.14. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The firm has a market cap of $10.34 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.44 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same period in the prior year, the business posted $0.55 earnings per share. The company's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on QGEN shares. Bank of America upped their price target on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Barclays started coverage on Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen cut Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. UBS Group increased their target price on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Finally, Cowen reissued a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.